A systematic review was conducted by using three different databases: Pub- Med, Web of Science, and EMBASE, in the period between January 2011 and May 2021. Studies on the use of FDG PET in BC patients concerning the utility of metric PET data and survival were retrieved. The following keywords were used in diverse combinations: \"breast cancer\", \"18F-FDG\", \"FDG\", \"PET\", \"PET/CT\", \"FDG PET\", \"volumetric parameters\", \"metabolic tumor volume\", \"MTV\", \"total lesion glycolysis\", \"TLG\", \"prognosis\", \"prognostic\". No limits were applied. The quality of selected papers was assessed by using specific criteria.
Totally 123 articles were retrieved, but only 14 studies were selected. In the selected papers, overall, the number of patients was 1850. Overall survival (OS) was the main outcome in three studies, while both OS and disease-free survival (DFS) were considered in the remainder of most papers. PET/CT was performed in patients with BC before surgery or neoadjuvant chemotherapy in 6 studies and in metastatic BC in 8. At multivariable analyses, diverse PET metrics, such as SUVmax, MTV, and TLG, were correlated to recurrence or OS. However, a large heterogeneity for the proposal cut-off, able to discriminate between poor and good prognosis, was found.
PET metrics are helpful for the prognosis stratification in patients with locally advanced or metastatic BC. However, no specific cut-off values for these variables are now available in this setting of patients.
方法:通过使用三个不同的数据库进行了系统评价:PubMed,WebofScience和EMBASE,在2011年1月至2021年5月期间。关于在BC患者中使用FDGPET的研究,关于公制PET数据的实用性和存活率进行了检索。以下关键字用于不同的组合:“乳腺癌”,\"18F-FDG\",\"FDG\",\"PET\",\"PET/CT\",\"FDGPET\",“体积参数”,“代谢性肿瘤体积”,\"MTV\",“总病变糖酵解”,\"TLG\",“预后”,\"预后\"。没有应用限制。通过使用特定标准来评估所选论文的质量。
结果:共检索到123篇文章,但只选择了14项研究。在选定的论文中,总的来说,患者人数为1850人。总生存期(OS)是三项研究的主要结果,而OS和无病生存期(DFS)在大多数论文的其余部分都被考虑。对BC患者进行PET/CT检查,手术前或新辅助化疗6项研究和转移性BC8项。在多变量分析中,不同的PET指标,例如SUVmax,MTV和TLG与复发或OS相关。然而,提案截止的巨大异质性,能够区分预后差和预后好,找到了。
结论:PET指标有助于局部晚期或转移性BC患者的预后分层。然而,在这种情况下,目前尚无这些变量的具体截止值.